Introduction
Chemo-radiotherapy (CRT) has increased the curability of locally advanced head and neck cancer patients (HNCPs) [1] and has allowed organ and function preservation in laryngeal and hypo-pharyngeal cancer patients [2] . However, competing causes of mortality (e.g. acute and late toxicities) are increased and substantially reduce the overall survival benefit [3, 4] .
In CRT trials the acute mortality is described in the range from 2% [5] to 9.3% [6] . Infection is one of the main causes of acute mortality [6, 7] .
Unfortunately, the reporting of infection is sparse even in randomized trials and the problem is likely underestimated.
There are three main limitations in interpreting data from CRT trials:
(1) Infection-related mortality can be confounded with other potential causes of death or categorized as "due to an unknown cause" [6] , as the recognition of sepsis requires an active search and finite criteria. Most importantly unexplained organ failure (renal, respiratory, cardiovascular, coagulation, multi-organ etc.) is often reported as the cause of death while the probable relationship with underlying sepsis syndrome is not recognized. (2) Organ damage due to the systemic inflammatory response is often misinterpreted as being related to the individual toxicities of the treatment. In a retrospective analysis of 394 patients enrolled in consecutive CRT phase II trials at the University of Chicago, 14 deaths were attributed to infection and eight cases of pneumonia were considered "comorbidities" [6] . In total, 22 deaths (5.6%) were certainly due to infectious complications. Another 10 deaths were classified as due to "unknown reasons" or due to factors that could possibly be related to sepsis (small bowel necrosis, cardiac causes, "other respiratory disease" etc.). In addition, only recently have the abscopal effects of local inflammation toxicity been described [8] [9] [10] . Treatments enhancing local toxicity seem to be related to a higher degree of severe complications and deaths [11] . (3) Finally, the infectious-related mortality is not limited to the time of CRT administration but can occur several weeks after treatment [12] . Post-treatment infections and deaths are usually not considered treatment-related.
We feel that the lack of recognition of the connection between the single toxicities and the systemic consequences is due to insufficient knowledge about infection, sepsis and its sequelae. The definitions of these conditions have been evolving over the last 20 years. Consequently, the various specialists, such as medical oncologists (MOs), radiation oncologists (ROs), infectious disease physicians (IDPs) and critical care physicians (CCPs) treating HNCPs, use the terminology with different meanings. In fact, while years ago (before 1989) the term sepsis referred solely to a severe bacterial infection and was often confused with the infection itself, more recently sepsis has been defined as a systemic syndrome [13, 14] that encompasses multiple signs and symptoms resulting from the body's reaction to infectious systemic immune responses [15, 16] . Helpful to the understanding of sepsis is the definition of the Systemic Inflammatory Response Syndrome (SIRS), indicating the unique, highly preserved systemic response to tissue damage (either infectious or non-infectious) [14, 17] .
For all these reasons MOs, ROs, CCPs and IDPs from Italy met in Milan from February 17-18, 2013 with the aim of reaching a consensus on a clinical definition and management of infections and sepsis in CRT-treated HNCPs.
The results of the literature review and the statements that obtained consensus are reported and discussed in this paper.
Material and methods
The Delphi appropriateness method was used for this Consensus [18] .
The panel, a group of 37 multidisciplinary experts (MOs, ROs, IDPs, CCPs, nutritionists and nurses), met in Milan from February 17-18, 2013 and appointed a facilitator board of 12 expert members, from different clinical settings (6 MOs, 4 ROs and 1 IDP and 1 CCP). The facilitator board performed a systematic review of the literature on infection in CRT-treated HNCPs.
The MEDLINE database was searched for Englishlanguage studies published from 1992 to March 2013 containing the terms sepsis, head and neck cancer, nosocomial, healthcare-acquired, infections, chemotherapy (CT), and radiotherapy (RT).
Potentially relevant abstracts presented at annual meetings of the American Society of Clinical Oncology and of the European Society of Medical Oncology were examined. The study selection included the following: (a) observational and prospective studies about assessment and treatment; (b) randomized, double-blind, placebo-controlled, or uncontrolled studies; (c) retrospective and uncontrolled studies; (d) systematic reviews and meta-analyses; (e) consensus guidelines. Furthermore, the electronic search results were supplemented by manual examination of reference lists from selected articles.
On the basis of this literature review, the facilitators identified a number of key statements.
All the experts rated these statements through a two-round process. A 4-grade scale was used, where 1 was defined as high consensus, 2 was defined as low consensus, 3 was defined as no consensus, and 4 was chosen by panelists when they felt unable to express an opinion.
A web meeting was held before the second rating, where statements were discussed. The statements that received a weak approval (<75/100) were redefined according to the observations of panelists. The second ratings were analyzed to identify the statement that reached a consensus.
Each expert (including facilitators) was equally weighted in scoring the statements.
External MOs (JBV, BM), RO (JB), IDP (AC), supportive cancer care specialist (JR-D), and CCPs (MVR and RPD) reviewed the statements.
The panelists had a second meeting in Milan on May 5, 2014 in order to approve the final version of the statements.
Results
Consensus-reached statements are listed in Table 1 .
Comments

General statements
Epidemiology
The rate of infection during CRT is around 19%, the acute mortality of CRT is between 2% and 9.3% and the majority of deaths occurring within 30 days from the end of treatment is infection-related.
Definition of Sepsis syndrome
The panel adopted the nomenclature and definitions for terms used by 2001 International Sepsis Definitions [46, 47] and alcohol [48] consumption, malnutrition [82, 157] , swallowing impairment with aspiration [45] , chemotherapy-induced neutropenia [39, 158, 159] , disruption of physiological barriers as a consequence of radiodermitis and mucositis [40, 160] , gingival pockets and dental caries [161] [162] [163] [164] , age [12, 165, 166] , co-morbidities such as diabetes and chronic obstructive pulmonary disease (COPD) [166] , and the presence of central venous catheters, gastrostomy and tracheostomy are at a higher risk of infections. Conference (i.e. SIRS, sepsis, severe sepsis, and septic shock) ( Table 2) . Before 1989 [13, 14] , "sepsis" was considered to be a systemic infection, often described as "blood poisoning" and assumed to be the result of the host's invasion by pathogenic organisms that then spread within the bloodstream. After the advent of modern antibiotics, germ theory could not fully explain the pathogenesis of sepsis: researchers suggested that it is the host, not the germ, that drives the pathogenesis of sepsis [19] .
Recently a "Consensus conference" attempted to "provide a conceptual and practical framework to define the systemic inflammatory response to infection" [17] . The acronym SIRS (Systemic Inflammatory Response Syndrome) was used in order to provide a reference for the complex findings that result from a systemic activation of the immune response, triggered by a variety of infectious and noninfectious conditions. Yet, the identification of sepsis through the 1992-consensus SIRS criteria had a high sensitivity but a low specificity. Indeed, the same criteria can be found in non-infectious conditions [20] and may represent an appropriate physiological reaction [21, 22] . In 2001 an International Sepsis Definitions conference revisited the SIRS criteria (see Table 2 ) [23] by expanding the list of possible signs of systemic inflammation in response to infection to the physical and laboratory findings indicative of early organ dysfunction, altered tissue perfusion, and hemodynamic failure, as well.
Thus, even though the 1991 four criteria for sepsis continue to be used because they are easily measurable [24, 25] , in presence of suspected sepsis, the other items included in the 2001-consensus list in order that the presence of some degree of organ dysfunction, altered tissue perfusion, and/or hemodynamic failure have to be actively searched.
Etiology and pathogenesis of systemic inflammatory response syndrome (SIRS) and Sepsis in HNCPs
Any kind of tissue damage can induce a SIRS through circulating mediators. When this response is prolonged and associated with infection it can result in severe sepsis and related complications.
Recently the definition of immunity reactions has been revisited [26, 27] : either endogenous danger signals (danger/damage-associated molecular patterns -DAMPs) General parameters -Fever (core temperature >38.3 • C) -Hypothermia (core temperature <36 • C -Heart rate >90 bpm or >2 SD above the normal value for age -Tachypnea: >30 bpm -Altered mental status -Significant edema or positive fluid balance (>20 ml/kg over 24 h) -Hyperglycemia (plasma glucose >140 mg/dl or 7.7 mM/l) in the absence of diabetes Inflammatory parameters -Leukocytosis (white blood cell count >12,000/l) -Leukopenia (white blood cell count <4000/l) -Normal white blood cell count with >10% immature forms -Plasma C reactive protein >2 SD above the normal value -Plasma procalcitonin >2 SD above the normal value Hemodynamic parameters -Arterial hypotension (systolic blood pressure <90 mmHg, mean arterial pressure <70 mmHg, or a systolic blood pressure decrease >40 mmHg in adults or <2 SD below normal for age) -Mixed venous oxygen saturation >70% -Cardiac index >3.5 l min Organ dysfunction parameters -Arterial hypoxemia (PaO 2 /FIO 2 <300) -Acute oliguria (urine output <0.5 mL/kg/1 h or 45 mM/l for at least 2 h) -Creatinine increase ≥0.5 mg/dl -Coagulation abnormalities (international normalized ratio >1.5 or activated partial thromboplastin time >60 s) -Ileus (absent bowel sounds) -Thrombocytopenia (platelet count <100,000/l) -Hyperbilirubinemia (plasma total bilirubin >4 mg/dl or 70 mol/l) Tissue perfusion parameters -Hyperlactatemia (>1 mol/l) -Decreased capillary refill or mottling Severe Sepsis (Sepsis with organ dysfunction) a Symptoms and signs related to panoply of nonspecific inflammatory response and to dysfunctions of organs and of microvasculature.
Deteriorating evolution of systemic inflammation
Sepsis + organ dysfunctions (due to abnormal organ perfusion) in acutely ill patients Septic Shock a Sepsis + refractory (unresponsive to fluid and vasopressors) hypotension+ perfusion abnormality a Septicaemia was the archaic term to identify these syndromes. [20] . Legend: radiochemotherapy on the treated tissues causes damage that facilitates inflammation. Furthermore germs may more easily spread via the bloodstream after translocation through disrupted barriers: (1) mouth, (2) respiratory tract, (3) intestinal mucosa, (4) skin and (5) devices. Released cytokines act not only locally but also on other organs and tissues (Inter-organ signaling). On muscles they can alter energetic metabolism (thus favoring cachexia). On HPA (hypothalamic-pituitary-adrenal axis) they cause fever and fatigue symptoms. On the liver they provoke the synthesis of acute phase proteins that in turn act in a procoagulative and general inflammatory and anti-inflammatory sense. All these effects can lead to systemic inflammatory response syndrome (SIRS) or sepsis. Abbreviations: PaCO 2 = arterial carbon dioxide tension; MODS: Multi-organ Dysfunction Syndrome; Other abbreviations see the text. [28, 29] , generated by stressed host cells, or exogenous pathogen-associated molecular patterns (PAMPs) [30] [31] [32] are recognized as being capable of activating the pattern recognition receptors (PRRs) [33] of the immune cells and as promoting the synthesis of inflammation mediators. Thus, any kind of tissue damage (pathogens [34, 35] , CRT [8, 9] etc.) can induce a local [27, 36] and systemic inflammatory response through circulating mediators ( Fig. 1) [8, 9, 20] . Some Authors [37] postulated that anti-inflammatory mediators predominate within the bloodstream to avoid igniting new inflammatory foci, while their presence within tissues may not always be sufficient to prevent the initiation of a deleterious inflammatory response in various compartments [38] . Consequently, the sepsis/SIRS-patient plasma behaves as an immunosuppressive milieu [39] . A consequence of this deregulation is the fact that germs may more easily spread via the bloodstream after translocation through disrupted barriers (skin and mucosal barrier injury [40] ). Thus, it has become apparent that when prolonged or intensive host responses are provoked (infections, trauma, or CRT) [41] [42] [43] both pro-inflammatory and anti-inflammatory mechanisms (involving cytokines) can contribute to infection clearance, organ injury and secondary infections [44] (Fig. 1) . During CRT, HNCPs have a number of conditions predisposing to infection [45] , making them extremely at risk.
Predisposing factors
HNCPs with habits such as smoking [46, 47] and alcohol [48] consumption, malnutrition, swallowing impairment with aspiration, chemotherapy-induced neutropenia, disruption of physiological barriers as a consequence of radiodermitis and mucositis, gingival pockets and dental caries, age, co-morbidities such as diabetes and chronic obstructive pulmonary disease (COPD), and the presence of central venous catheters, gastrostomy and tracheostomy are at a higher risk of infections.
Statements about monitoring and diagnosis of sepsis
The early identification of sepsis and implementation of early therapies have been documented to improve outcomes and decrease sepsis-related mortality [49] . Reducing the time to diagnosis of severe sepsis is thought to be a critical component of reducing mortality from sepsis-related multiple organ dysfunction [50] . As oncological patients with sepsis are logically not different from other septic patients, the panel recommends an early diagnosis of sepsis by following the three main steps: Table 3 Infection probability score a (IPS) [51] . [23] , be performed as a regular procedure [22] . Another important role of the assessment of SIRS criteria can be the evaluation of patients with local tissue damage or infection. In CRT-treated HNCPs the occurrence of stomatitis, in-field skin toxicity, or device-related skin infection can be either a local limited phenomenon or a systemic evolving response [20] . The latter deserves a timely application of systemic treatment. Thus, more frequent analysis (at least daily) of SIRS criteria has the potential of capturing the systemic evolution of a local inflammation and of orienting all the following management strategies.
Recently, Peres Bota et al. [51] developed an infection probability score (IPS) which uses six variables (Table 3) to assess the likelihood of infection, resulting in a score from 0 to 26: the 14 score cut-off proved to be reliable enough (positive predictive value = 53.6%; negative predictive value = 89.5%) in distinguishing infectious (≥14) from non-infectious (<14) SIRS. In addition, changes in IPS over time may be useful in following the response to antimicrobial therapy [52] . The first step in assessing the patient with suspected sepsis is to determine the actual risk of infection and the likely source by obtaining information regarding colonizing or infecting pathogens: the nature of any localizing symptoms and signs should be noted. At any rate, the altered immune function may not present the typical sign of inflammation and may occult the localizing signs. Thus, any suspected source must be examined (skin, presence of devices, leg thrombosis, neck, mucosae and lungs.) SIRS-positive HNCPs should undergo laboratory, microbiological, and radiological evaluation after an infection probability assessment based on history and physical examination.
The diagnosis of Sepsis
-Laboratory evaluation
• Thrombocytosis, thrombocytopenia, hyperglycemia, metabolic acidosis, and changes in the inflammatory status. Even though TNF, IL-1, IL-6, IL-8, and IL-10 are all important in sepsis, they are not specific for inflammation/organ dysfunction, and do not assist in distinguishing between infectious and non-infectious causes.
• C-Reactive Protein (C-RP) and/or procalcitonin, although not always associated with infection [53] [54] [55] [56] [57] [58] , can add useful information about its diagnosis. -C-RP levels > 17 mg/dl have been suggested as providing a means of separating patients with sepsis from those with non-septic inflammatory response due to other causes (e.g. trauma) [59] . -Procalcitonin has been proposed as a marker of infection [60] [61] [62] [63] . Furthermore, it may be useful as an indicator of the severity of infection and as a guide for therapy (dose de-escalation [64] ) in respiratory infections [61, 62, [65] [66] [67] [68] .
Thus, these markers cannot be recommended distinguishing between severe infection and other acute inflammatory states [69] , but they can be helpful adjunctive diagnostic markers to be interpreted in context with information from careful medical history, physical examination.
-Microbiological evaluation: Obtaining cultures before antimicrobial administration is essential to confirm infection, to appropriately target antibiotic therapy and to allow antimicrobial de-escalation after receipt of the susceptibility profile [70] . Unfortunately, positive results are obtained only in one third of the cases and their negativity does not rule out the presence of infection [71] . Considering that the first antimicrobial dose can rapidly sterilize blood cultures within a few hours, obtaining those cultures before therapy is essential. Thus, at least two blood cultures, both peripherally and via indwelling catheters are recommended [70, [72] [73] [74] . Although some guidelines [70] recommend that cultures should not cause significant delay (>45 min) in starting antimicrobial administration, some authors suggest that non-neutropenic and stable patients should be observed without empirical antibiotics while considering further diagnostic evaluation [75] .
If fungal infection is suspected, 1-3b-d-glucan, mannan and anti-mannan antibody assays have shown positive results significantly earlier than with standard culture methods [70] . False positive reactions can occur with colonization alone [76] .
Microbiological samples should also be taken from sites that are suspected of being infected.
-Radiological evaluation:
In order to identify the infection sources, imaging may help. Ultrasonography, performed at the bedside, can assist in localizing a fluid collection and may allow for percutaneous drainage and microbial cultures. CT scanning can help identify thoracic, abdominal, and deep-space infections. White Indium 111 -labeled blood-cell scans and indium 111 Immunoglobulin-G have poor sensitivity and specificity, whereas Technetium scans seems to be more useful, owing to its high specificity (93-94%), but it has a poor sensitivity (40-75%) [77] . Finally, Fluorodeoxyglucose positron-emission tomography (FDG-PET) scans have a high sensitivity (95%) and a good specificity (88%) in identifying septic sources in patients with fever of unknown origin [77] [78] [79] . [80] [81] [82] . Thus, assessment of bone marrow, renal, liver, brain, coagulation, respiratory and circulatory functions through laboratory examinations and clinical monitoring should always be associated with the search for the infection site (Table 4 ).
The evaluation of organ dysfunction
The term "severe sepsis" was proposed to describe instances in which sepsis is complicated by inadequate tissue perfusion or organ dysfunction [83] . Capillary bed hypo-perfusion causes dysoxia, due to both altered microcirculation ("supply-dependent dysoxia") [83, 84] and the inhibition of mitochondrial respiratory enzymes caused by toxic oxygen and nitrogen intermediates ("cytopathic hypoxia") [85, 86] .
Other causes of peripheral hypoxia are the myocardial contractility depression, owing to a variety of myocardial depressants found in the septic-patient plasma (such as TNFa, IL-1, IL-6 and nitric oxide) [87, 88] , and the acute lung injury due to damage to the pulmonary vascular circulation and the alveolar-capillary membranes.
As a consequence of the above-mentioned causes, the circulatory abnormalities (intravascular volume depletion, peripheral vasodilatation, myocardial depression) and increased metabolism lead to an imbalance between systemic oxygen delivery/demand, resulting in global tissue hypoxia or even shock. As the cardiovascular system is designed to preserve arterial blood pressure to maintain cerebral and coronary perfusion during stress by reducing perfusion to peripheral tissues, the routine vital signs, central venous pressure and urinary output [89, 90] may be relatively insensitive measures of early circulatory shock (also known as "cryptic shock" [90] ), whereas serum lactate levels can serve as a marker of occult hypoperfusion [91, 92] . Indeed, patients with cryptic hypoperfusion are often overlooked as candidates for aggressive interventions because they are hemodynamically stable [93] , but they are associated with increased mortality [92, [94] [95] [96] [97] . Thus, the main endpoint in sepsis treatment is to recognize the imbalance between oxygen delivery/demand measuring serum lactate in order to start resuscitation promptly [70, 93] (the so called Early Goal directed therapy (EGDT)). Current critical care guidelines recommend measuring serum lactate in hemodynamicallystable patients with sepsis to assess for occult hypoperfusion, since an elevated lactate level (≥4 mmol/L) may warrant ICU transfer. Recent evidence (non-randomized trials) suggests that the serum lactate threshold used to identify patients eligible for EGDT be lowered, given the association between modestly elevated serum lactate levels (≥2 mmol/L) and morbidity and mortality [70, 96, 97] . This transition point (lactate≥2/4 mmol/L) occurs during the critical "golden hours" when treatment can provide maximum benefits in terms of outcome [93] . Thus, EGDT policy aims to restore this balance promptly by manipulating cardiac contractility, oxygenation, and tissue perfusion.
The parameters that monitor this balance between oxygen delivery/demand include mixed oxygen saturation (pulmonary-artery oxyhemoglobin saturation representing total balance of oxygen consumption and delivery assuming ability of cells to take up oxygen) (SvO 2 ) or central venous saturation (ScvO 2 ) (superior half-body oxygen saturation), lactate production, base deficit and pH [98] . Yet, one of the problems in the applicability of these guidelines is the need Table 4 The goal of supportive treatment: restoration and maintenance of adequate tissue perfusion so as to prevent multiple organ dysfunctions.
Goal
Clinical Table 4 lists the parameters that need checking in order for organ dysfunctions to be monitored.
Statements about hospitalization and antineoplastic treatment interruption 4.3.1.1. Hospitalization
HNCPs with sepsis should be promptly hospitalized as this condition can progress rapidly.
CT interruption
For suspected or confirmed severe sepsis during CRT, CT should be the first treatment to be interrupted.
RT interruption
For suspected or confirmed sepsis during CRT, RT should be stopped only in particularly compromised patients or in the presence of severe sepsis.
Sepsis management requires multidisciplinary (oncologist/hematologist, IDP, CCP, nurses, pneumonologists, and dieticians), diagnostic and management actions that need to interact rapidly in order to maximize the chances of success [70] . Thus, the panel suggests that HNCPs undergoing CRT should be hospitalized when diagnostic criteria for sepsis [23] are associated with a suspected infection. This is so that HNCPs can progress more rapidly and that the specific antineoplastic treatments can continue safely by limiting interruption as much as possible.
In addition, the presence of sepsis should induce the interruption of CT administration, given its potential in worsening organ damage and in hindering immune responses. CT should be resumed when every organ failure is resolved and no sign of SIRS is present. Conversely, the radiotherapeutical systemic effects are less dangerous than chemotherapeutical ones: consequently, the panel suggests continuing RT as the advantage due to local-toxicity recovering could be annulled by the negative effects of tumor re-growth [106, 107] . Of course, the symptoms of local toxicity must be monitored/controlled. 
Statements about the Early empirical antimicrobial treatment
Empirical antibiotic therapy should be started within 3 h of clinical presentation 4.4.2 For suspected or confirmed sepsis (Systemic inflammatory response to infection; see
.4.7 For healthcare-associated infections non-responsive to the first line of antibiotics, the IDPs' assessment is mandatory
Initiation of therapy may be necessary for unstable or high-risk patients while the diagnostic evaluation is ongoing [75] . If an infectious cause of fever is suspected, empirical antimicrobial therapy is urgent. Indeed, delaying effective antimicrobial therapy has been associated with increased mortality [49, [110] [111] [112] [113] [114] . Barie and associates [115] demonstrated in a prospective observational study that the delayed-antibiotic therapy increased the risk of death by 2.1% for every 30 minutes' delay (OR, 1.021; 95% CI, 1.003 to 1.038). Moreover, MacArthur et al. in a randomized trial obtained a 10% decrease in the overall crude-mortality with an adequate and early empirical antibiotic treatment [116] . Thus, antibiotics should be given before obtaining the results of cultures in any case suspected of having an infection and when one or more organ failures are manifested without other signs of infection.
The initial selection of antimicrobial therapy should be broad enough to cover all likely pathogens [110] [111] [112] 115, 117, 118] . Kollef et al. showed [117] that the prior administration of antibiotics (implying an increased risk of resistant pathogens) and the presence of a bloodstream infection (especially catheter-related: implying resistant gram positive cocci and failure to treat fungemia empirically) were the main causes of inappropriate therapy and increased mortality.
Initial empirical anti-infective therapy includes one or more drugs that have activity against all likely pathogens (considering both Gram+ and Gram-and/or fungal or viral) and that penetrate in adequate concentrations into the tissues presumed to be the source of sepsis [70] (Table 5) .
Thus, the main aims that should guide the choice of antiinfective treatments are [69, 70] : Table 5 Proposals from the literature of empiric antibiotic antimicrobial choice based on suspected site of infection.
Presume Site of the source of infection
Local infection or critical colonization Sepsis a , b
Pneumonia c Early onset, low risk for multi-drug resistant organisms: Out-patient: ceftriaxone plus azithromycin 500 mg qd or levofloxacin 500 mg bid or moxifloxacin po 400 mg qd In-patient (IV) ampicillin/sulbactam 3 g q8 h, (IV) ceftriaxone plus (IV) azithromycin 500 mg qd or levofloxacin 750 mg qd or moxifloxacin400 mg qd(IV)
Late onset and/or risk factors for MDR organisms:
Meropenem ( Moxifloxacin 400 mg intravenously (IV) qd followed by moxifloxacin 400 mg orally (PO) qd [183, 184] or Amoxicillin/clavulanate and ciprofloxacin plus metronidazole [185] In a If the patient is "antibiotic experienced" an amynoglicoside rather than a quinolone or cephalosporin for gram-is advisable. In fact certain microorganisms, chiefly Enterobacteriaceae (e.g., E. coli and K. pneumoniae), contain a beta-lactamase enzyme that inactivates penicillins and cephalosporins (Extended Spectrum Beta-Lactamase producing bacteria (ESBL) Patients presenting with ESBL-associated risk factors (intra-abdominal), tigecycline is recommended [185] .
b The combined antibiotic therapy should consider pathogens with antibiotic resistance (such as MRSA, Pseudomonas species, and gram-negative organisms with ESBL activity) increasing the likelihood that at least one drug may be effective against that strain [187, 188] .
c Typically require dual broad-spectrum antibiotics with overlapping coverage [189] [190] [191] [192] . d In patients with a history of IV drug use, those with indwelling vascular catheters or devices, or those with recent hospitalizations an agent such as daptomycin (in absence of pneumonia) or vancomycin (IF mic ≤1) or linezolid (in absence of bacteremia) should be adopted.
e Cephamycins (e.g., cefotetan) and carbapenems (e.g., imipenem, meropenem, and ertapenem) [193] remain effective against ESBL-producing organisms.
-The evaluation of risks for infection by multidrug-resistant pathogens.
HNCPs having been treated with CT during the previous 30 days should be considered immunocompromised [119] [120] [121] and at high risk of healthcare-associated infections.
-The evaluation of the suspected infection source
The main infection sources in HNCPs are the respiratory tract, the oral cavity, and medical devices such as central venous catheters (CVCs) [122] , especially total implanted access ports [123] , gastrostomy [124] , and tracheostomy [47] .
• Respiratory infection is the most frequent non-cancer cause of morbidity/death in HNCPs. Indeed, Soares [82] and Downey [125] reported that the main reasons for ICU admission for HNCPs were sepsis and acute respiratory failure. Other authors [126, 127] showed that the most common causes of non-cancer-associated morbidities/death are respiratory diseases. Indeed, aspiration of colonized oropharyngeal contents into the lower respiratory tract can be due to HNCPs' swallowing dysfunction [45, 128] . Thus, pneumonia in HNCPs should be considered and treated according to the health-care acquired pneumonia (HCAP) criteria due to the frequent involvement of multidrug resistance organisms [121] .
• Regarding the oral cavity, a systematic review shows that clinical oral fungal infection/colonization rises respectively to 37.4%/72% during RT and 38%/74.5% during CT. Candida albicans (46.2%) was the prevalent colonizing fungi followed by C. tropicalis (16.6%) [129] . Furthermore, shifts in oral bacterial flora (mainly from streptococci toward coagulase-positive staphylococci) [130] ) have been attributed to CT, xerostomia, antibiotic use and associated neutropenia [130] [131] [132] .
• Regarding device-related infection, it must be considered that a colonized foreign body serves as a continuing source of infection by multiple mechanisms: it impairs local host defenses and many of the organisms have the capacity to form a biofilm on invasive devices and so create a continuing focus of infection. Coagulase-negative Staphylococci species, for example, create a biofilm and therefore are a common cause of vascular catheter-related infections [133] . The infection due to these external-internal devices may be localized to entrance-site and/or tunnel (or port-pocket in the case of port-a-cath CVC) and, when associated to SIRS, is the cause of device-associated "blood systemic infection" (BSI). Cancer patients with implantable port systems experienced a median of 0.2 infections per 1000 catheter-days (range: 0-2.7 per 1000 catheter-days) [134] versus a risk that ranges from 1.4 to 2.2 infections per 1000 catheter-days for subcutaneous tunneled CVCs [135, 136] . Nevertheless, this difference may be biased by the fact that patients who receive implantable subcutaneous ports usually receive much less intensive cancer therapy [137] . Thus, the optimal device to be used during CRT is hardly advisable and needs further prospective trials.
Recommendations for culturing and treatment of catheter-related BSI are addressed by the Infectious Diseases Society of America [138, 139] . In addition, ASCO guidelines [137] • Regarding the enteral nutrition, there were significantly more infections in the PEG group (66%) compared to the NGT group (30%) p = 0.001 in the prospective study of Corry et al. [124] , but the difference of pneumonia between the two groups (PEG = 31.3% vs. NGT = 30%) was statistically insignificant. In fact, the majority of infections in the PEG group were at the PEG site (31%: 10/32).
-Evaluation of antimicrobial sensitivity of local germ populations.
The prevalence of microorganisms differs according to the environments. Some authors [140] have observed that gram-positive bacteria prevail over the gram-negative ones as infectious pathogen in developed countries, probably because of the routine use of prophylactic oral antibiotics (such as quinolones, which can also favor bacteriaceae) [141] and the use of CVC [140] . Conversely gram-negative prevails in developing countries [142] .
Consequently, most scientific guidelines [70, 120] recommend recognizing the variability of bacteriology from one hospital to another over time in order to select the most appropriate antibiotic regimen.
Statement about the antibiotic de-escalation procedure
The empirical treatment must be optimized when microbiology results are available
The empirical combination antimicrobial therapy should not be administered for longer than 3-5 days [70] . After that period, treatment de-escalation to the most appropriate single-agent therapy should be performed as soon as the susceptibility profile is known [109] . This should minimize the risk of inducing toxicity and bacterial resistance, and of developing superinfections with other resistant organisms such as Candida species, Clostridium difficile or vancomycin-resistant Enterococcus faecium. Concern about under treatment due to de-escalation is unfounded [143] . The "Surviving sepsis campaign" [70] suggests the duration of therapy be 7-10 days if clinically indicated; longer courses may be appropriate in patients who have a slow clinical response, undrainable foci of infection, bacteremia with MRSA; some fungal and viral infections, or immunological deficiencies, including neutropenia.
The use of procalcitonin [64, 144, 145] or similar biomarkers may facilitate discontinuance of antibiotics in a patient with clinical improvement, although one recent study failed to show any benefit of daily procalcitonin measurement [146] . Table 4 ) should be rapidly referred to an intensive care unit (ICU) In 2004, the "Surviving Sepsis Campaign" guidelines recommended the use of EGDT [147] based on one large randomized trial [93] . These guidelines were updated in 2008 [148] , successively in 2012 [70] , and were further supported by several subsequent trials that corroborated the benefit of EGDT in severe sepsis and septic shock [149] .
Statements about early goal-directed treatment (EGDT)
Rivers [93] showed there was an increase in survival at 28 days through EGDT application in a randomized study in which patients with severe sepsis and septic shock received EGDT during the first 6 h after enrolment or the usual therapy. EGDT involves identifitcation of high-risk patients (see Table 4 ), invasive monitoring, and 6 hours of protocolled resuscitation with fluids, vasoactive agents, and packed red blood cells. Although these strategies are common in the ICU, they are not in oncology or internal medicine wards. Recently, some authors have not found any significant benefit of the mandated use of central venous catheterization and central hemodynamic monitoring in all patients [102] .
The mechanisms of the benefit of EGDT are unknown but may include reversal of tissue hypoxia and a decrease in inflammation and coagulation defects.
Statement about the follow up
Monitoring for SIRS parameters should be continued after the end of CRT until the complete resolution of acute toxicities. Indeed, mortality for pneumonia is reported to occur well after 30 days from the end of treatments and there is a high risk of infection for several months
Mortality for pneumonia is reported to occur well beyond 30 days after the end of treatments and a high risk of infection is maintained for several months [6, 12] . Indeed, it must be considered that the local damage and nutritional impairment last several months after the end of treatment [150] , consequently the risk of infection remains higher well after the end of treatment.
Conclusions
The sepsis in CRT-treated HNCPs is a serious much-feared complication and constitutes a reason for treatment reduction, delay, or interruption. It may affect the prognosis and cause the death of potentially curable patients. In order to better manage this adverse event, it is necessary to standardize clinical definitions, diagnosis, management, and treatment according to international guidelines. Since very little has been written concerning severe sepsis in HNCPs, our review aimed to obtain some indications for the management of septic patients from literature and tried to draw up recommendations/suggestions for HNCPs, based on the consensus among multidisciplinary health professionals. The main aim is to standardize their diagnostic and treatment behavior.
Obviously, the main limit of this study is the fact that most literature is obtained from non-HNCPs.
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